Shirish Gadgeel is a Lung Cancer Treatments and Mutations physician affiliated with Henry Ford Health System. OpenAlex indexes 859 publications with 43,144 citations (h-index 79); ClinicalTrials.gov lists 18 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Shirish Gadgeel, MD, is affiliated with Henry Ford Health System. The public record shows 859 publications with 43,144 citations (h-index 79), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 36 companies, 1 NIH-funded awards (2014–2015).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lung Cancer Treatments and Mutations
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 36 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 29 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 293.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Sponsor: SWOG Cancer Research Network
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Sponsor: SWOG Cancer Research Network
- Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC
Sponsor: Shirish Gadgeel
Industry payments
Updated 14 Oct 2026
36 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year202513 payments$15,522openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year202512 payments$12,822openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
58.3%Kinase inhibitor50.6%Tagrisso53%Alecensa22%Retevmo12%Tabrecta12%Part D<11 patientsOther antineoplastic agents4.5%Lumakras100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
9.8%Serotonin-3 Receptor Antagonist6.5%Ondansetron Odt100%Part D≥19 patientsPotassium supplement3.3%Potassium Chloride100%Part D<11 patientsSensory organs
8%Corticosteroid8%Dexamethasone100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2014–2015 per NIH RePORTER. The latest:
- Profiling Genetic Alterations in NSCLC in African Americans
Wayne State University
FY2015$231,420R21CA184778 - Profiling Genetic Alterations in NSCLC in African Americans
Wayne State University
FY2014$132,240R21CA184778
Congress activity
Updated 14 Oct 2026
196 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 406: Discovery of potent and selective TRIB2 inhibitors with therapeutic efficacy in therapy-resistant neuroendocrine prostate cancer.
AACR Annual Meeting
AACR2026Co-author - Abstract 3065: Tribbles 2 drives lineage maintenance and survival in neuroendocrine prostate cancer by regulating N-Myc stability
AACR Annual Meeting
AACR2025Co-author - Abstract 5624: The antiviral, Daclatasvir, disrupts ASCL1-EZH2 signaling and impairs survival of neuroendocrine prostate cancer cells
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1.
Journal of clinical oncology
Guideline2026 - Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Journal of clinical oncology
Clinical Trial2026 - TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors.
Clinical cancer research
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerArticle6,677 citations2018
- 02
- 03Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung CancerArticle2,485 citations2017
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/shirish-gadgeel-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/shirish-gadgeel-062162245
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
obrpodcast.libsyn.com/website/2025/04
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →obrpodcast.libsyn.com ↗ - Other
henryford.com/blog/tags/shirish-gadgeel
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →henryford.com ↗ - Other
ilcn.org/shirish-gadgeel-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ilcn.org ↗ - Other
lungcancerresearchfoundation.org/new-sab-members-2024-04-30
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lungcancerresearchfoundation.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Kalkanis, MD
Henry Ford Health System
Mani Menon, MD
Henry Ford Health System
Marcus Zervos, MD
Henry Ford Health System
Firas Abdollah, MD
Henry Ford Health System
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center